Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Their lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.

Duane Burnett

Gerhard Koenig

Arkuda Therapeutics

Jaya Biosciences is a privately held pre-clinical stage life sciences company developing therapies for genetically defined neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and frontotemporal dementia.

Jaya Biosciences

Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.

Michael J. Fox Foundation

Pfizer Venture Investments

Mission BioCapital

Atlas Venture

Tekla Capital Management

Pivotal bioVenture Partners

Surveyor Capital

Cormorant Asset Management

Eli Lilly

This week at the Alzheimer's Association® International Conference, Arkuda Therapeutics will present preclinical data on lead development candidate ARKD-104, a novel oral therapeutic in development for the treatment of GRN-related frontotemporal dementia. The study showed treatment with ARKD-104 markedly increased progranulin levels – critical to restoring lysosomal function in not only FTD-GRN but in other neurodegenerative diseases. Learn more: https://lnkd.in/enX_JJcg

#progranulin #granulin #lysosome #endFTD #Alzheimers

Congrats to Thomas Kukar's lab (+ Arkuda team members Chris Holler, Ph.D., Bonne Thompson, Giuseppe Astarita, and Jean-François Blain) on this critically important work demonstrating the important role that granulins play in FTD. 

The team at Arkuda Therapeutics continues to advance drug candidates which modulate both progranulin and granulins towards clinical studies, with the goal of someday offering novel treatments for FTD and other neurodegenerative diseases. 

#granulins #ftd #therapeutics #neurodegeneration #neurodegenerativediseases

https://lnkd.in/gmEx-CQb

Congratulations to Raymond Hurst and the rest of the Arkuda Therapeutics team for a great presentation at #adpd2023, "Therapeutic Potential of ARKD-104 for Treatment of Frontotemporal Dementia and Other Neurodegenerative Diseases"

Wishing everyone a happy International Women's Day!

Today and every day we celebrate the incredible achievements of women in different aspects of life all over the world.  We are committed to an inclusive workplace which recognizes the importance of collective activism in driving sustainable change, and aspire towards a world in which we all #EmbraceEquity.

 #IWD2023

Metric
Company Name	Arkuda Therapeutics	Jaya Biosciences
Symbol
MSH ID	COM:ARKUDATX	COM:JAYABIO
Market	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	US
Stage	Series B
Employee Count	28
Website	arkudatx.com	jayabio.com
LinkedIn	arkudatx
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	66
Web Traffic Growth	-0.95
Valuation
Raised Capital	64M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ARKUDATX

Arkuda Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue